Navigation Links
Protocol for a clinical study on reduced toxicant prototype cigarettes published
Date:7/28/2013

British American Tobacco has published the protocol for a clinical study designed to determine whether using reduced-toxicant prototype cigarettes that reduce smokers' exposure to smoke toxicants impacts biological effect (ISRCTN81286286).

The study protocol refers to the 'recipe' used to conduct a study, describes what will be done during the study, how this will be done and why it is being done.

This study follows a previous study by researchers at British American Tobacco that showed that it is possible to reduce smokers' exposure to certain smoke toxicants by switching them to novel prototype cigarettes with lower amounts of some toxicants in the smoke (doi:10.1016/j.yrtph.2013.02.007). This was a short-term study, lasting six weeks. Now a second clinical study will assess whether this reduced exposure is maintained over the longer term, and also whether longer term exposure reduction results in detectable changes in biological effect.

The prototype cigarettes used in both studies contained technologies designed to reduce key toxicants in smoke. A resin that removes aldehydes and a nano-porous carbon that traps volatile smoke compounds were added to the filter. An enzyme-treatment was used on the tobacco to remove proteins and polyphenols that become toxicants when burned, and inert calcium carbonate and glycerol were added to dilute the smoke.

BAT combined these technologies into three different prototype cigarettes and showed in a clinical study that there was a reduction in exposure to certain toxicants in smokers who switched to the prototype cigarettes for six weeks.

However, that study was not long enough to explore the potential for a reduction in risk of smoking-related diseases or adverse biological effects. Now a longer-term (six months) study will determine whether use of prototype cigarettes leads to both continued reductions in exposure to toxicants and beneficial changes in the body, as shown by assessment of selected biomarkers. The protocol for this new study has been approved by an independent ethics committee and is published in BioMed Central Public Health.

The six-month single-centre, single-blinded, controlled switching study with periods of clinical confinement is being conducted in Germany. A total of 260 healthy adult subjects were recruited into the study; 140 smokers, 60 former smokers and 60 never-smokers (ISRCTN81286286). The demographically matched non-smokers serve as a comparison group because some toxicant exposure stems from dietary and environmental sources. The non-smokers also provide reference levels for biomarkers of biological effect.

Smokers are randomly assigned to a control or test group. Both groups smoke a control product for two weeks, at which point baseline measurements of biomarker levels are made. Smokers in the control group then continue to smoke the control product for a further 24 weeks, while smokers in the test group switch to the prototype cigarette. Urine, saliva and blood samples are taken from all smokers at 4, 9, 13 and 24 weeks after the switch. Biomarkers of exposure and biological effect are then measured.

Changes in biomarker levels are analysed at baseline, midpoint and end of the study. Levels within individuals are compared before and after switching, while those between individuals are evaluated by comparing smokers who switched with those who didn't.

Data from this study are expected to improve the scientific understanding of tobacco products. Changes in biomarkers of biological effect may add to the body of evidence of the potential of toxicant reducing technologies in reducing disease risk.

"There are already tobacco and nicotine products available, such as snus and e-cigarettes, that are known to pose substantially lower risk than cigarettes. And we don't know whether it will be possible to scientifically prove that reduced toxicant cigarettes reduce health risks,' said Dr David O'Reilly, Group Scientific Director at British American Tobacco. 'But,' he said, 'we believe reducing smokers' exposure to cigarette smoke toxicants continues to be an important research objective, given the numbers of people who smoke and the numbers who are likely to continue to smoke for the foreseeable future.'


'/>"/>

Contact: Dr. Marina Murphy
marina_murphy@bat.com
44-077-111-50135
R&D at British American Tobacco
Source:Eurekalert

Related medicine news :

1. New treatment protocol extends survival in some cases of once inoperable pancreatic cancer
2. Researchers develop secure protocol for linking data registries for HPV surveillance
3. ASTRO: Deviating from radiation protocols increases risk of treatment failure and death
4. Dr. Robbins Updates HCG EZ Drops Diet Protocols
5. Comprehensive maternal hemorrhage protocols improve patient safety
6. Delgado Protocol Announces Adrenal DMG, An Amazing New Supplement Designed to Support the Immune, Circulatory and Cardiovascular Systems
7. Standard CT protocol for trauma patients leads to overutilization of imaging
8. Audiology Associates Explains New Hearing Aid Protocol in Honor of Better Hearing and Speech Month
9. Delgado Protocol For Health Introduces Stay Young, A Powerful New Anti-Aging Supplement
10. Keller Family Dental Explains their Infection Control Protocols
11. PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology: